Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02617667 · ClinicalTrials.gov registry record · Phase 2
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
A Phase 2 study of Dry Eye Syndromes, sponsored by Novaliq.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
- 4
- Study locations
NCT02617667 is a Phase 2 study of Dry Eye Syndromes that has completed, run by Novaliq. The registered enrollment target is 207 participants, below the 402-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (49% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02617667, a Phase 2 study of Dry Eye Syndromes, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
- 4
- Study locations
Study Summary
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry Eye Disease (DED).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cyclosporine A
Study Locations (4)
Massachusetts
- CYS-002 Investigational Site - Andover
- CYS-002 Investigational Site - Quincy
California
- CYS-002 Investigational Site - Newport Beach
Maine
- CYS-002 Investigational Site - Lewiston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02617667
The ClinicalTrials.gov registry entry for NCT02617667 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 402-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (49% lower). The listed sponsor is Novaliq, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02617667 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, California, Maine.
Frequently Asked Questions
What is clinical trial NCT02617667 about?
NCT02617667 is a clinical study titled "CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)". The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry Eye Disease (DED).
What is the current status of trial NCT02617667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2016-01. Estimated completion is 2016-09.
What conditions does trial NCT02617667 study?
This clinical trial studies the following conditions: Dry Eye Syndromes.
What interventions are being tested in trial NCT02617667?
The interventions under investigation include: Placebo (DRUG), Cyclosporine A (DRUG).
Who is sponsoring clinical trial NCT02617667?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02617667 being conducted?
This trial has 4 study locations across California, Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye
COMPLETED · Phase 2
-
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
COMPLETED · Phase 2
-
Dry Eye Assessment and Management: Feasibility Study
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.
COMPLETED · Phase 2
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.